Details:

Alternative Title:
Hum Vaccin Immunother
Publisher's site:
http://dx.doi.org/10.1080/21645515.2018.1451810
Personal Author:
Dretler, A. W. ; Rouphael, N. G. ; Stephens, D. S.
Dretler, A. W. ; Rouphael, N. G. ; Stephens, D. S. Less -
Description:
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global implementation. Meningococcal protein-polysaccharide conjugate vaccines to serogroups A, C, W, and Y (modeled after the Haemophilus influenzae b conjugate vaccines) provide better duration of protection and immunologic memory, and overcome weak immune responses in infants and young children and hypo-responsive to repeated vaccine doses seen with polysaccharide vaccines. ACWY conjugate vaccines also interfere with transmission and reduce nasopharyngeal colonization, thus resulting in significant herd protection. Advances in serogroup B vaccine development have also occurred using conserved outer membrane proteins with or without OMV as vaccine targets. Challenges for meningococcal vaccine research remain including developing combination vaccines containing ACYW(X) and B, determining the ideal booster schedules for the conjugate and MenB vaccines, and addressing issues of waning effectiveness.
Subject:
[+]
Epidemiology
Meningitis
Meningococcemia
Neisseria Meningitidis
Polysaccharide- Protein Conjugate Vaccine
Polysaccharide Vaccines
Review

Source:
Hum Vaccin Immunother. 2018; 14(5):1146-1160.
Pubmed ID:
29543582
Pubmed Central ID:
PMC6067816
Document Type:
Journal Article
Funding:
CC/CDC HHS/United States
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:1594d884fccbeb6432ddb028cfe3995cef254ed15bacbf5e78b39c8733380678
File Type:

Supporting Files

• 	khvi-14-05-1451810-g001.gif	gif
  	khvi-14-05-1451810-g001.jpg	jpeg
  	khvi-14-05-1451810.nxml	xml

More +